Clinical trial
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
NCT00014183 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00014183 |
|---|---|
| Title | ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer |
| Official title | A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | National Cancer Institute (NCI) NIH University of Maryland Greenebaum Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | gefitinib |
| Start date | Jan 1, 2001 |
| Primary completion | May 1, 2002 |
| Completion | Aug 1, 2005 |
| First posted | Jan 1, 2004 |
| Last update posted | Nov 7, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: